New options for treatment of candidaemia in critically ill patients.
Bloodstream infections caused by Candida spp. are increasingly recognised in critically ill adult and paediatric individuals, with significant associated morbidity and mortality. Candida albicans is the single most common fungal species to cause nosocomial infections. However, non-C. albicans spp., including Candida glabrata and Candida krusei, which are less susceptible to fluconazole, have become more common. Until the 1980s, the therapeutic possibilities for invasive candidosis were limited to amphotericin B, but with the advent of new antifungal agents, such as azoles and echinocandins, less toxic therapeutic options have become available and there are now possibilities for prevention and optimised therapy for documented Candida infections. In this review, the currently available options for the treatment of candidaemia and invasive candidosis are discussed with regard to the role of liposomal amphotericin B in comparison with the echinocandins and azoles.
Ruhnke
M
M
Medizinische Klinik und Poliklinik II, Charité Campus Mitte der Humboldt-Universität zu Berlin, Berlin, Germany. markus.ruhnke@charite.de
Hartwig
K
K
Kofla
G
G
D000666:Amphotericin B / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage*; D001393:Azoles / Q000008:administration & dosage; D002175:Candida / Q000254:growth & development*; D002177:Candidiasis / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D000077336:Caspofungin; D016638:Critical Illness; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000008:administration & dosage; D016469:Fungemia / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D055666:Lipopeptides
D000935:Antifungal Agents; D001393:Azoles; D054714:Echinocandins; D055666:Lipopeptides; D000666:Amphotericin B; D000077336:Caspofungin